Fintel reports that on December 16, 2024, Jefferies upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from Hold to Buy.
Analyst Price Forecast Suggests 7.74% Upside
As of December 3, 2024, the average one-year price target for Bristol-Myers Squibb is $60.10/share. The forecasts range from a low of $33.43 to a high of $76.65. The average price target represents an increase of 7.74% from its latest reported closing price of $55.78 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Bristol-Myers Squibb is 49,029MM, an increase of 3.36%. The projected annual non-GAAP EPS is 8.29.
What is the Fund Sentiment?
There are 3,435 funds or institutions reporting positions in Bristol-Myers Squibb. This is an increase of 90 owner(s) or 2.69% in the last quarter. Average portfolio weight of all funds dedicated to BMY is 0.32%, an increase of 7.37%. Total shares owned by institutions increased in the last three months by 0.87% to 1,803,424K shares. 
The put/call ratio of BMY is 0.88, indicating a bullish outlook.
What are Other Shareholders Doing?
Jpmorgan Chase holds 77,930K shares representing 3.84% ownership of the company. In its prior filing, the firm reported owning 74,630K shares , representing an increase of 4.23%. The firm decreased its portfolio allocation in BMY by 91.87% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 64,248K shares representing 3.17% ownership of the company. In its prior filing, the firm reported owning 64,141K shares , representing an increase of 0.17%. The firm increased its portfolio allocation in BMY by 17.21% over the last quarter.
Charles Schwab Investment Management holds 61,030K shares representing 3.01% ownership of the company. In its prior filing, the firm reported owning 59,062K shares , representing an increase of 3.23%. The firm increased its portfolio allocation in BMY by 1.58% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 53,098K shares representing 2.62% ownership of the company. In its prior filing, the firm reported owning 52,027K shares , representing an increase of 2.02%. The firm increased its portfolio allocation in BMY by 17.01% over the last quarter.
SCHD - Schwab U.S. Dividend Equity ETF holds 48,017K shares representing 2.37% ownership of the company. In its prior filing, the firm reported owning 42,521K shares , representing an increase of 11.45%. The firm increased its portfolio allocation in BMY by 25.16% over the last quarter.
Bristol-Myers Squibb Background Information
(This description is provided by the company.)
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
